Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
According to the recently published report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2?) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.
The report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022' outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Wilson Disease.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2?) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.
The report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022' outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Wilson Disease.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development
AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Apic Bio Inc
Avrion Therapeutics AG
Biogen Inc
Collaborative Medicinal Development LLC
Novartis Gene Therapies
ProMIS Neurosciences Inc
ResQ Biotech
Thera Neuropharma Inc
Voyager Therapeutics Inc
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles
ALN-SOD - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
APB-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVR-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVXS-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cu(II)ATSM - Drug Profile
Product Description
Mechanism Of Action
History of Events
NU-9 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Peptides to Inhibit Superoxide Dismutase (SOD1) for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
SOD1 - Drug Profile
Product Description
Mechanism Of Action
TDI-186 - Drug Profile
Product Description
Mechanism Of Action
THN-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
tiomolibdate choline - Drug Profile
Product Description
Mechanism Of Action
History of Events
tofersen sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYSOD-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYSOD-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones
Featured News & Press Releases
Jul 27, 2022: FDA grants priority review for Biogen’s tofersen to treat ALS
Jul 26, 2022: Ionis announces that FDA accepts New Drug Application and grants priority review of tofersen for a rare, genetic form of ALS
Jun 23, 2022: ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson Disease community
Jun 03, 2022: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Jun 03, 2022: New 12-month tofersen data presented at ENCALS meeting show clinically meaningful benefit in people with SOD1-ALS
Nov 18, 2021: Neurimmune and TVM Capital Life Science announce the initiation of AL-S Pharma's phase 2 Study of AP-101 for the treatment of ALS
Oct 18, 2021: Biogen’s tofersen fails to meet primary goal in Phase III ALS trial
Oct 17, 2021: Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
Oct 14, 2021: Topline results from Tofersen phase 3 study and its open label extension in SOD1-ALS to be presented at the American Neurological Association Annual Meeting
Aug 27, 2021: Alexion’s drug meets primary goal in Phase III Wilson disease trial
Jul 28, 2021: Apic Bio receives FDA fast track designation for APB-102 for the treatment of patients with SOD1 ALS
Apr 21, 2021: Apic Bio announces FDA clearance of IND application for lead gene therapy candidate APB-102 for the treatment of SOD1 ALS
Feb 23, 2021: ALS neuron damage reversed with new compound
Jul 23, 2020: Investigational drug for genetic form of ALS showing early promise, trial indicates
Jul 13, 2020: New treatment for motor neurone disease shows promise in early trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development
AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Apic Bio Inc
Avrion Therapeutics AG
Biogen Inc
Collaborative Medicinal Development LLC
Novartis Gene Therapies
ProMIS Neurosciences Inc
ResQ Biotech
Thera Neuropharma Inc
Voyager Therapeutics Inc
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles
ALN-SOD - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
APB-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVR-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVXS-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cu(II)ATSM - Drug Profile
Product Description
Mechanism Of Action
History of Events
NU-9 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Peptides to Inhibit Superoxide Dismutase (SOD1) for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
SOD1 - Drug Profile
Product Description
Mechanism Of Action
TDI-186 - Drug Profile
Product Description
Mechanism Of Action
THN-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
tiomolibdate choline - Drug Profile
Product Description
Mechanism Of Action
History of Events
tofersen sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYSOD-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYSOD-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones
Featured News & Press Releases
Jul 27, 2022: FDA grants priority review for Biogen’s tofersen to treat ALS
Jul 26, 2022: Ionis announces that FDA accepts New Drug Application and grants priority review of tofersen for a rare, genetic form of ALS
Jun 23, 2022: ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson Disease community
Jun 03, 2022: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Jun 03, 2022: New 12-month tofersen data presented at ENCALS meeting show clinically meaningful benefit in people with SOD1-ALS
Nov 18, 2021: Neurimmune and TVM Capital Life Science announce the initiation of AL-S Pharma's phase 2 Study of AP-101 for the treatment of ALS
Oct 18, 2021: Biogen’s tofersen fails to meet primary goal in Phase III ALS trial
Oct 17, 2021: Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
Oct 14, 2021: Topline results from Tofersen phase 3 study and its open label extension in SOD1-ALS to be presented at the American Neurological Association Annual Meeting
Aug 27, 2021: Alexion’s drug meets primary goal in Phase III Wilson disease trial
Jul 28, 2021: Apic Bio receives FDA fast track designation for APB-102 for the treatment of patients with SOD1 ALS
Apr 21, 2021: Apic Bio announces FDA clearance of IND application for lead gene therapy candidate APB-102 for the treatment of SOD1 ALS
Feb 23, 2021: ALS neuron damage reversed with new compound
Jul 23, 2020: Investigational drug for genetic form of ALS showing early promise, trial indicates
Jul 13, 2020: New treatment for motor neurone disease shows promise in early trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AL-S Pharma AG, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Alnylam Pharmaceuticals Inc, 2022
Pipeline by Apic Bio Inc, 2022
Pipeline by Avrion Therapeutics AG, 2022
Pipeline by Biogen Inc, 2022
Pipeline by Collaborative Medicinal Development LLC, 2022
Pipeline by Novartis Gene Therapies, 2022
Pipeline by ProMIS Neurosciences Inc, 2022
Pipeline by ResQ Biotech, 2022
Pipeline by Thera Neuropharma Inc, 2022
Pipeline by Voyager Therapeutics Inc, 2022
Dormant Projects, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AL-S Pharma AG, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Alnylam Pharmaceuticals Inc, 2022
Pipeline by Apic Bio Inc, 2022
Pipeline by Avrion Therapeutics AG, 2022
Pipeline by Biogen Inc, 2022
Pipeline by Collaborative Medicinal Development LLC, 2022
Pipeline by Novartis Gene Therapies, 2022
Pipeline by ProMIS Neurosciences Inc, 2022
Pipeline by ResQ Biotech, 2022
Pipeline by Thera Neuropharma Inc, 2022
Pipeline by Voyager Therapeutics Inc, 2022
Dormant Projects, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
